首页|参脉注射液与阿托伐他汀治疗冠心病慢性心力衰竭患者的效果

参脉注射液与阿托伐他汀治疗冠心病慢性心力衰竭患者的效果

扫码查看
目的 探究参脉注射液与阿托伐他汀治疗冠心病慢性心力衰竭患者的效果.方法 将本院2016年4月~2017年4月所收治的冠心病慢性心力衰竭患者44例纳入本次研究设为对照组,实施常规对症治疗,并加用阿托伐他汀;并将同期接收的另外44例冠心病慢性心力衰竭患者设为研究组,在对照组基础上联用参脉注射液予以治疗,比较2组间疗效.结果 研究组经过治疗干预之后,患者中医证候总有效率相比较对照组更高(P<0.05);左室射血分数(LVEF)、左室舒张末内径(LVEDD)、左室收缩末内径(LVESD)等心功能改善状况显著优于对照组(P<0.05);血清超敏C反应蛋白(hs-CRP)、脑钠肽(BNP)、血浆肿瘤坏死因子-α(TNF-α)水平相比较治疗前有明显的降低,且下降幅度显著高于对照组(P<0.05);组间不良反应发生率比较差异无统计学意义.结论 在冠心病慢性心力衰竭患者中采用参脉注射液与阿托伐他汀联合治疗,可以在取得良好疗效的同时,改善患者的心功能,安全性较高,可在临床上进一步推广及应用.
Clinical effect of Shenmai injection and atorvastatin in treating coronary heart disease of chronic heart failure
Objective To explore clinical effect of Shenmai injection and atorvastatin in treating coronary heart disease of chronic heart failure(CHF). Methods 44 patients with coronary heart disease of chronic heart failure from April 2016 to April 2017 were included in this study as control group. They were treated with conventional symptomatic treatment, and combined with atorvastatin. 44 cases with coronary heart disease patients of chronic heart failure at the same period received as study group, they were treated with Shenmai injection based on the treatment of the control group,compared the curative effect between two groups. Results After treatment intervention,the total effective rate of TCM syndrome of the study group is higher than the control group(P<0.05). Left ventricular ejection fraction(LVEF),left ventricular end-diastolic diameter (LVEDD), left ventricular systolic diameter(LVESD) of cardiac function improved significantly better than control group(P<0.05); Serum hypersensitive c-reactive protein (hs-CRP),brain natriuretic peptide(BNP),plasma tumor necrosis factor alpha (TNF alpha) levels, compared with before treatment were significantly lower,and decreased significantly than that of control group(P<0.05). Incidence of adverse reactions was no significant difference between groups. Conclusion Shenmai injection and atorvastatin in treating coronary heart disease of chronic heart failure can achieve significant clinical effect and improve the patients' heart function, high safety, worthy of further popularization and application in clinic.

Shenmai injectionatorvastatincoronary heart disease patients with chronic heart failureeffect

杜惠莲

展开 >

宁夏固原市隆德县人民医院 心血管内科,宁夏 固原 756300

参脉注射液 阿托伐他汀 冠心病慢性心力衰竭患者 效果

2017

中国生化药物杂志
南京生物化学制药研究所,全国生化制药情报中心站,中国生化制药工业协会,中国药品生物制品检定所

中国生化药物杂志

ISSN:1005-1678
年,卷(期):2017.37(9)
  • 5
  • 11